Masahiro Tsuboi

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Masahiro Tsuboi, Jie He et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial

Hisashi Saji, Morihito Okada, Masahiro Tsuboi et al. · The Lancet · 2022 · 1.5K citations

Surgical Oncology, Medicine, Cancer Management +10

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

Heather A. Wakelee, Moïshe Liberman, Terufumi Kato et al. · New England Journal of Medicine · 2023 · 903 citations · Full text

A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung

Harubumi Kato, Yukito Ichinose, Morio Ohta et al. · New England Journal of Medicine · 2004 · 828 citations · Full text

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

Shogo Kumagai, Yosuke Togashi, Takahiro Kamada et al. · Nature Immunology · 2020 · 785 citations

Cancer Immunosurveillance, Autoimmune Disease, T-regulatory Cell +12